Abivax’s Obefazimod Advances in Ulcerative Colitis Treatment
Abivax’s Obefazimod Advances in Ulcerative Colitis Treatment Paris, France – 12 January 2026 – Abivax SA has made significant strides in the development of obefazimod, its first-in-class oral miR-124 enhancer, for the treatment of moderately to severely active ulcerative colitis (UC). Following positive Phase 3 induction trial results announced in July 2025, the company is […]
Abivax’s Obefazimod Advances in Ulcerative Colitis Treatment Read More »
